Cholylglycine ELISA Kit

Erum Cholygllycine (Cholygllycine, CG) is a combination of secondary bile acids with glycine conjugated bile acids, in liver cells, cholesterol, after its complex enzymatic reaction, turn into the primary bile acid. Cholic acid (CA) and chenodeoxycholic acid (the CD-CA) . Bile acid steroid nucleus three hydroxyl groups (C3, C7, C12), the side chain hydroxyl at the end of the peptide bond and glycine combined with a molecular weight of 462u. CG normal metabolic pathways of the intestine - liver circulation, CG synthesized by hepatocytes, bile canaliculi, bile duct discharged into the gall bladder, along with the bile into the duodenum to help digestion of food. 95% of bile acid reabsorption in the distal ileum, come back to the liver via the portal vein, and uptake by the liver cells to re-use. Exist in the form of protein binding in serum, the total amount of overflow into the systemic circulation is less than 1%. Under normal circumstances, bile acid content in the peripheral blood, leaving little room for normal adults, whether fasting or postprandial serum CG concentration stabilized at a low level. When liver cells are damaged, the liver cell uptake CG capacity decreased, resulting in increased CG content in the blood; cholestasis, liver excretion of bile acids that barriers to reflux of blood circulation increased CG content, but also to the blood CG levels increased. Therefore, the determination of serum glycocholic acid (SCG) by ELISA method is a sensitive indicator to evaluate the function of liver cells and their hepatobiliary material circulation. Normal serum Cholygllycine: 1.3 ± 0.8mg / L, range 0.4 to 2.98mg / L, and the low limit of the hepatitis diagnosis <3.18mg / L

Aviva Systems Biology Cholyglycine ELISA Kit (OKEH02529) is based on a competitive enzyme immunoassay technique. The microtiter well-plate in this kit has been pre-coated with an anti-Cholyglycine antibody. Sample or standards are added to the wells along with a fixed quantity of biotinylated Cholyglycine and incubated. The Cholyglycine found in the sample or standards competes with the biotinylated Cholyglycine for limited binding sites on the immobilized anti-Cholyglycine antibody. Excess unbound biotinylated Cholyglycine and sample or standard Cholyglycine is washed from the plate. Avidin-HRP conjugate is added, incubated and washed. An enzymatic reaction is then produced through the addition of TMB substrate which is catalyzed by the immobilized HRP to generate a blue color product that changes yellow after adding acidic stop solution. The density of yellow coloration is measured by reading the absorbance at 450 nm which is quantitatively proportional to the amount of biotinylated Cholyglycine captured in the well and inversely proportional to the amount of Cholyglycine which was contained in the sample or standard.

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol